Inclusion Body Myositis clinical trials at University of California Health

3 in progress, 0 open to eligible people

Showing trials for

  • ABC008 for Inclusion Body Myositis

    Sorry, in progress, not accepting new patients

    A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis

    at UC Irvine UCLA UCSF

  • Ulviprubart (ABC008) in Subjects with Inclusion Body Myositis

    Sorry, in progress, not accepting new patients

    ABC008-IBM-202 is an open-label, multicenter study to evaluate the safety and efficacy of long-term administration of ulviprubart (ABC008) in subjects with IBM who have completed either Study ABC008-IBM-101 or Study ABC008-IBM-201. Subjects may be enrolled in this study if they meet study eligibility criteria and: - Have completed the Part 2 (Multiple Ascending Dose [MAD]) End of-Treatment (EOT) Visit in Study ABC008-IBM-101; subjects who continued further on into Part 3 of the study (MAD Extension) prior to enrolling in this study are also eligible; OR - Have completed the Week 80 Follow-up Visit in Study ABC008-IBM-201.

    at UC Irvine

  • Sporadic Inclusion Body Myositis Natural History Study

    Sorry, in progress, not accepting new patients

    This is a prospective natural history study on patients with clinically defined sIBM. Participants will be assessed every 6 months over two years (five visits total). We will include 150 participants, enrolled across 13 sites, with sporadic IBM, diagnosed according to established criteria.

    at UC Irvine UCLA

Our lead scientists for Inclusion Body Myositis research studies include .

Last updated: